UCB SA's psoriatic arthritis drug bimekizumab significantly improved joint and skin symptoms in a phase 2b trial.
Psoriatic arthritis is an inflammatory condition affecting the joints and skin.
The study met its primary goal with up to 46% of psoriatic arthritis patients who received the treatment seeing at least 50% improvement in joint symptoms after 12 weeks, compared with 7% of patients on placebo.
Among patients with skin lesions, 65% of those who received the drug experienced at least 90% skin clearance at week 12, compared with 7% who received placebo.
Bimekizumab has also demonstrated its efficacy in treating ankylosing spondylitis, a type of arthritis that mainly affects the spine. In a phase 2b study, 47% of patients receiving bimekizumab achieved at least 40% improvement in disease symptoms, compared to 13% receiving placebo after 12 weeks.